Post-Operative Pain - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 165 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Operative Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H1 2015', provides an overview of the Post-Operative Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Post-Operative Pain Overview 11
Therapeutics Development 12
Pipeline Products for Post-Operative Pain - Overview 12
Pipeline Products for Post-Operative Pain - Comparative Analysis 13
Post-Operative Pain - Therapeutics under Development by Companies 14
Post-Operative Pain - Therapeutics under Investigation by Universities/Institutes 17
Post-Operative Pain - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Post-Operative Pain - Products under Development by Companies 21
Post-Operative Pain - Products under Investigation by Universities/Institutes 23
Post-Operative Pain - Companies Involved in Therapeutics Development 24
A. Menarini Industrie Farmaceutiche Riunite Srl 24
AcelRx Pharmaceuticals, Inc. 25
Adynxx, Inc. 26
AngioChem Inc. 27
Boehringer Ingelheim GmbH 28
Cara Therapeutics, Inc. 29
Chong Kun Dang Pharmaceutical Corp. 30
Cytogel Pharma, LLC 31
DURECT Corporation 32
Echo Pharmaceuticals B.V. 33
Encore Therapeutics Inc. 34
Flexion Therapeutics, Inc. 35
Galleon Pharmaceuticals 36
Grunenthal GmbH 37
GW Pharmaceuticals plc 38
Heron Therapeutics, Inc. 39
Immupharma Plc 40
INSYS Therapeutics, Inc. 41
Laboratorios Del Dr. Esteve S.A. 42
Medtronic, Inc. 43
Ocular Therapeutix, Inc. 44
Omeros Corporation 45
Orbis Biosciences, Inc. 46
Orion Oyj 47
Pharmazz, Inc. 48
PhytoHealth Corporation 49
Recro Pharma, Inc. 50
Rottapharm SpA 51
Takeda Pharmaceutical Company Limited 52
Thar Pharmaceuticals, Inc. 53
Trevena, Inc. 54
UMeWorld Limited 55
Post-Operative Pain - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
(bupivacaine hydrochloride + meloxicam) - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
(ketoprofen + amitriptyline + oxymetazoline) - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
(ketorolac tromethamine + phenylephrine hydrochloride) - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AM-4 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ANG-2002 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ARX-01 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ARX-8028 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ARX-8203 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
AYX-1 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
BI-1026706 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
bupivacaine hydrochloride - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
bupivacaine hydrochloride liposomal - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
bupivacaine hydrochloride SR - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
buprenorphine hydrochloride - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
centhaquine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CKD-943 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CMX-020 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
CR-4056 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
CR-845 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Cyt-1010 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
dexamethasone acetate SR - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
dexmedetomidine hydrochloride - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
dronabinol - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
E-52862 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
fadolmidine hydrochloride - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
FX-007 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
GAL-044 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
GIBH-1014 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
grapiprant - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
IPP-102199 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
ketamine hydrochloride ER - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
MDT-10013 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
nabiximols - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
nalbuphine hydrochloride - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
ropivacaine - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
ropivacaine ER - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
T-109 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
tapentadol hydrochloride - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
tramadol hydrochloride - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
TRV-130 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
VVZ-149 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Post-Operative Pain - Recent Pipeline Updates 126
Post-Operative Pain - Dormant Projects 153
Post-Operative Pain - Discontinued Products 155
Post-Operative Pain - Product Development Milestones 156
Featured News & Press Releases 156
Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain 156
Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS 158
Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain 158
Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain 159
Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130 159
Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN 159
Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain 160
May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program 161
May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting 161
May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain 162
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165

List of Tables
Number of Products under Development for Post-Operative Pain, H1 2015 12
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 24
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015 25
Post-Operative Pain - Pipeline by Adynxx, Inc., H1 2015 26
Post-Operative Pain - Pipeline by AngioChem Inc., H1 2015 27
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2015 28
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H1 2015 29
Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 30
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H1 2015 31
Post-Operative Pain - Pipeline by DURECT Corporation, H1 2015 32
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2015 33
Post-Operative Pain - Pipeline by Encore Therapeutics Inc., H1 2015 34
Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H1 2015 35
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H1 2015 36
Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2015 37
Post-Operative Pain - Pipeline by GW Pharmaceuticals plc, H1 2015 38
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H1 2015 39
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2015 40
Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H1 2015 41
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 42
Post-Operative Pain - Pipeline by Medtronic, Inc., H1 2015 43
Post-Operative Pain - Pipeline by Ocular Therapeutix, Inc., H1 2015 44
Post-Operative Pain - Pipeline by Omeros Corporation, H1 2015 45
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H1 2015 46
Post-Operative Pain - Pipeline by Orion Oyj, H1 2015 47
Post-Operative Pain - Pipeline by Pharmazz, Inc., H1 2015 48
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H1 2015 49
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H1 2015 50
Post-Operative Pain - Pipeline by Rottapharm SpA, H1 2015 51
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 52
Post-Operative Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2015 53
Post-Operative Pain - Pipeline by Trevena, Inc., H1 2015 54
Post-Operative Pain - Pipeline by UMeWorld Limited, H1 2015 55
Assessment by Monotherapy Products, H1 2015 56
Assessment by Combination Products, H1 2015 57
Number of Products by Stage and Target, H1 2015 59
Number of Products by Stage and Mechanism of Action, H1 2015 61
Number of Products by Stage and Route of Administration, H1 2015 63
Number of Products by Stage and Molecule Type, H1 2015 65
Post-Operative Pain Therapeutics - Recent Pipeline Updates, H1 2015 126
Post-Operative Pain - Dormant Projects, H1 2015 153
Post-Operative Pain - Discontinued Products, H1 2015 155